This Schedule 14A filing consists of communications from Paratek Pharmaceuticals, Inc., a Delaware
corporation (the Company), to the Companys employees relating to the Agreement and Plan of Merger, dated June 6, 2023, by and among the Company, Resistance Acquisition, Inc., a Delaware corporation (Parent) and
Resistance Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (the Merger Agreement).
In connection with the
filing of the definitive proxy statement on Schedule 14A, the following press release was issued by the Company on August 2, 2023:
Paratek Pharmaceuticals Filed its Definitive Proxy Statement and Letter to Stockholders in Connection
with Acquisition by Gurnet Point Capital and Novo Holdings
Transaction Provides Paratek Stockholders with Immediate Value and Liquidity
Stockholders to Receive Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85
per Share on Achievement of a Commercial Milestone for a total potential value of $3.00 per Share
Special Meeting of Stockholders to be Held on September 18, 2023 at 9 a.m. ET
BOSTON, August 2, 2023 (GLOBE NEWSWIRE) Paratek Pharmaceuticals, Inc. (Paratek) (Nasdaq: PRTK), a commercial-stage biopharmaceutical
company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that it has filed definitive proxy materials and a letter to Paratek stockholders with the
U.S. Securities and Exchange Commission in connection with the Companys previously announced definitive agreement to be acquired by Gurnet Point Capital (Gurnet Point) and Novo Holdings A/S (Novo Holdings). Paratek will
commence mailing the definitive proxy statement and letter to its stockholders on or about August 2, 2023.
The special meeting of stockholders of
Paratek will be held virtually via live webcast on Monday, September 18, 2023, at 9 a.m. ET.
The board of directors of Paratek recommends that
stockholders vote FOR each of the proposals listed on the WHITE proxy card enclosed with the definitive proxy statement.
Stockholders who have questions about voting their proxy are encouraged to contact our proxy solicitor Morrow Sodali LLC at +1
(800) 662-5200 (toll-free in North America), +1 (203) 658-9400 (collect outside of North America) or PRTK@info.morrowsodali.com
The full text of Parateks letter to stockholders follows:
Dear Fellow Paratek Stockholders,
I, together with all of my
fellow directors, are pleased to present you with the opportunity for the Company to be acquired at a significant premium to our unaffected stock price. The Board unanimously determined that the transaction is in your best interest. Now we are
asking for you to vote FOR the transaction at a special meeting of stockholders.
As you saw, on June 6, 2023, we announced a
definitive agreement to be acquired by Gurnet Point Capital and Novo Holdings A/S.
As a stockholder, upon closing of the transaction you will receive
both an immediate cash payment of $2.15 per share plus a contingent value right (CVR) of $0.85 per share payable upon the achievement of a net sales threshold for NUZYRA. This represents an aggregate potential total value of $3.00 per
share.